



Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 30, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 30, 2024-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 2:40 p.m. ET.

Interested parties can access the live webcast [here](#). An archived copy of the webcast will be available on the [events section](#) of the company's [investor relations website](#) for approximately 90 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on [X](#), [LinkedIn](#), [Facebook](#), and [YouTube](#).

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20240130180434/en/>

Media Contact

Will Zasadny
Inizio Evoke Comms
(619) 961-8848
will.zasadny@inizioevoke.com
media@sprucebio.com

Investors

Samir Gharib
President and CFO
Spruce Biosciences, Inc.
investors@sprucebio.com

Source: Spruce Biosciences, Inc.